Researchers at Vanderbilt University Medical Center (VUMC) are leading a nationwide study to determine the rate of novel coronavirus infection in U.S. children and their families.

A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.

RSV infection reduces the risk of infection with human rhinovirus, which could have implications for vaccine development and prevention strategies for viral respiratory tract infections in infants.

The National Institutes of Health (NIH) recently announced it will provide $157 million in awards to launch a multi-center, seven-year initiative that will investigate how exposure to environmental factors in early development — from conception through early childhood — influences the health of children and adolescents.

Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).

Four physicians from Vanderbilt University Medical Center (VUMC) have been elected to membership in two of the nation’s oldest and most respected medical honor societies — the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI).